{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:08:31Z","timestamp":1793214511678,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00296-021-04995-0","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T02:47:13Z","timestamp":1632451633000},"page":"2233-2239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: a case-based review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-5705","authenticated-orcid":false,"given":"Marko","family":"Bare\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3074-1646","authenticated-orcid":false,"given":"Mirna","family":"Reihl Crnogaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4940-0577","authenticated-orcid":false,"given":"Branimir","family":"Ani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"issue":"1","key":"4995_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55\u201378","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"4995_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology psoriatic arthritis. Rheum Dis Clin North Am 41(4):545\u2013568","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"4995_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.semarthrit.2010.07.004","volume":"40","author":"I Saougou","year":"2011","unstructured":"Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA (2011) Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40(5):398\u2013406","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"4995_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E (2017) CNS Demyelination with TNF-\u03b1 Blockers. Curr Neurol Neurosci Rep 17(4):36","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"4995_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrneurol.2011.1","volume":"7","author":"X Bosch","year":"2011","unstructured":"Bosch X, Saiz A, Ramos-Casals M, BIOGEAS Study Group (2011) Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 7(3):165\u201372","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"4995_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/JID.2015.350","volume":"136","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR (2016) Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 136(1):93\u201398","journal-title":"J Invest Dermatol"},{"issue":"6","key":"4995_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D et al (2017) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76(6):1101\u20131136","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4995_CR8","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar4582","volume":"16","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA (2014) Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16(3):R125","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4995_CR9","first-page":"122","volume":"25","author":"J Kaine","year":"2019","unstructured":"Kaine J, Song X, Kim G, Hur P, Palmer JB (2019) Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data. J Manag Care Spec Pharm. 25(1):122\u201332","journal-title":"J Manag Care Spec Pharm."},{"issue":"12","key":"4995_CR10","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awp289","volume":"132","author":"V Brucklacher-Waldert","year":"2009","unstructured":"Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E (2009) Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132(12):3329\u20133341","journal-title":"Brain"},{"issue":"3","key":"4995_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1365-2133.2008.09005.x","volume":"160","author":"I L\u00f3pez-Lerma","year":"2009","unstructured":"L\u00f3pez-Lerma I, Iranzo P, Herrero C (2009) New-onset psoriasis in a patient treated with interferon beta-1a. Br J Dermatol 160(3):716\u2013717","journal-title":"Br J Dermatol"},{"issue":"1","key":"4995_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"JS Tzartos","year":"2008","unstructured":"Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM et al (2008) Interleukin-17 production in central nervous system-infiltrating T Cells and Glial Cells is associated with active disease in multiple sclerosis. Am J Pathol 172(1):146\u2013155","journal-title":"Am J Pathol"},{"issue":"6","key":"4995_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/135245859600100619","volume":"1","author":"R Hohlfeld","year":"1996","unstructured":"Hohlfeld R (1996) Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler Houndmills Basingstoke Engl 1(6):376\u2013378","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"7412","key":"4995_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nature11307","volume":"488","author":"AP Gregory","year":"2012","unstructured":"Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F et al (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488(7412):508\u2013511","journal-title":"Nature"},{"issue":"12","key":"4995_CR15","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862\u20132869","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4995_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","volume":"32","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K (2013) New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol 32(2):271\u2013275","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4995_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10067-013-2419-8","volume":"33","author":"A Theibich","year":"2014","unstructured":"Theibich A, Dreyer L, Magyari M, Locht H (2014) Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol 33(5):719\u2013723","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4995_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G et al (2013) Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey. Rheumatol Oxf Engl 52(5):868\u2013874","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"4995_CR19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW van Oosten","year":"1996","unstructured":"van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47(6):1531\u20131534","journal-title":"Neurology"},{"issue":"3","key":"4995_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","year":"1999","unstructured":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study (1999) The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology 53(3):457\u201365","journal-title":"Neurology"},{"issue":"4","key":"4995_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242\u2013251","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4995_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez Null, Diaz-Lagares C, Cuadrado M-J, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 9(3):188\u201393","journal-title":"Autoimmun Rev."},{"issue":"12","key":"4995_CR23","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1352458511412996","volume":"17","author":"AJ Solomon","year":"2011","unstructured":"Solomon AJ, Spain RI, Kruer MC, Bourdette D (2011) Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler Houndmills Basingstoke Engl 17(12):1472\u20131487","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"5","key":"4995_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1684\/ejd.2015.2558","volume":"25","author":"Y Honda","year":"2015","unstructured":"Honda Y, Otsuka A, Egawa G, Inoue Y, Kuzuya A, Takahashi R et al (2015) Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-\u03b1 therapy in psoriatic arthritis. Eur J Dermatol EJD 25(5):487\u2013488","journal-title":"Eur J Dermatol EJD"},{"issue":"1","key":"4995_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","volume":"244","author":"JH Chung","year":"2006","unstructured":"Chung JH, Stavern GPV, Frohman LP, Turbin RE (2006) Adalimumab-associated optic neuritis. J Neurol Sci 244(1):133\u2013136","journal-title":"J Neurol Sci"},{"key":"4995_CR26","doi-asserted-by":"publisher","first-page":"577525","DOI":"10.1016\/j.jneuroim.2021.577525","volume":"353","author":"M Lucchini","year":"2021","unstructured":"Lucchini M, Giuffr\u00e8 GM, Nociti V, Bianco A, De Fino C, Losavio FA et al (2021) Defining the disease course of TNF\u03b1 blockers-associated Multiple Sclerosis. J Neuroimmunol. 353:577525","journal-title":"J Neuroimmunol."},{"key":"4995_CR27","doi-asserted-by":"publisher","first-page":"175628641989515","DOI":"10.1177\/1756286419895155","volume":"13","author":"S Engel","year":"2020","unstructured":"Engel S, Luessi F, Mueller A, Schopf RE, Zipp F, Bittner S (2020) PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-\u03b1 therapy-associated demyelinating disorders. Ther Adv Neurol Disord 13:1756286419895155","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"4995_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MAJ.0b013e31822b7bb8","volume":"342","author":"K Nozaki","year":"2011","unstructured":"Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL et al (2011) Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 342(5):352\u2013355","journal-title":"Am J Med Sci"},{"issue":"8","key":"4995_CR29","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","volume":"198","author":"Q Wu","year":"2017","unstructured":"Wu Q, Wang Q, Mao G, Dowling CA, Lundy SK, Mao-Draayer Y (2017) Dimethyl fumarate selectively reduces memory T Cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients. J Immunol 198(8):3069\u201380","journal-title":"J Immunol"},{"issue":"3","key":"4995_CR30","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","volume":"2","author":"CM Spencer","year":"2015","unstructured":"Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BAC, Zamvil SS (2015) Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2(3):e76","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"4995_CR31","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","volume":"3","author":"CC Gross","year":"2016","unstructured":"Gross CC, Schulte-Mecklenbeck A, Klinsing S, Posevitz-Fejf\u00e1r A, Wiendl H, Klotz L (2016) Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(1):e183","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4995_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y (2018) Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol 9:5","journal-title":"Front Neurol"},{"issue":"12","key":"4995_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098\u20131107","journal-title":"N Engl J Med"},{"issue":"12","key":"4995_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087\u20131097","journal-title":"N Engl J Med"},{"issue":"4","key":"4995_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/14737175.2015.1025755","volume":"15","author":"D Dubey","year":"2015","unstructured":"Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T et al (2015) Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 15(4):339\u2013346","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"4995_CR36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/1352458519828601","volume":"25","author":"N Kumar","year":"2019","unstructured":"Kumar N, Abboud H (2019) Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler Houndmills Basingstoke Engl 25(8):1079\u20131085","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"6","key":"4995_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6):659\u2013674","journal-title":"Drugs"},{"issue":"6","key":"4995_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","volume":"15","author":"L Aly","year":"2017","unstructured":"Aly L, Hemmer B, Korn T (2017) From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis. Curr Neuropharmacol 15(6):874\u2013891","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"4995_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD et al (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73(2):349\u2013356","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4995_CR40","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K et al (2014) Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"7","key":"4995_CR41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","volume":"263","author":"E Havrdov\u00e1","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A, Tisserant A, Wright A, Wallstroem E et al (2016) Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol 263(7):1287\u20131295","journal-title":"J Neurol"},{"key":"4995_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16035","author":"M Venturini","year":"2019","unstructured":"Venturini M, Zanca A, Venturuzzo A, Filippini M, Frassi M, Tincani A et al (2019) Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. J Eur Acad Dermatol Venereol JEADV. https:\/\/doi.org\/10.1111\/jdv.16035","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"3","key":"4995_CR43","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1111\/1346-8138.14619","volume":"46","author":"GT Assefa","year":"2019","unstructured":"Assefa GT, Kaneko S, Oguro H, Morita E (2019) Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. J Dermatol 46(3):e112\u2013e113","journal-title":"J Dermatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04995-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04995-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04995-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:52:56Z","timestamp":1635249176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04995-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4995"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04995-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}